CDBIO(SH:688739) Xin Lang Cai Jing·2025-09-16 01:32Core Insights - Chengda Biological experienced a 0.50% decline in stock price on September 15, with a trading volume of 48.15 million yuan [1] - The company reported a financing net purchase of 1.62 million yuan on the same day, with a total financing and securities balance of 269 million yuan as of September 15 [1] Financing Summary - On September 15, Chengda Biological had a financing purchase of 5.41 million yuan, with a current financing balance of 268 million yuan, representing 2.33% of its market capitalization [1] - The financing balance is above the 90th percentile of the past year, indicating a high level of financing activity [1] Securities Lending Summary - On September 15, the company repaid 491 shares in securities lending and sold 2,786 shares, amounting to a selling value of 77,000 yuan [1] - The current securities lending balance is 918,500 yuan, with a remaining quantity of 33,200 shares, which is above the 80th percentile of the past year [1] Financial Performance - As of June 30, Chengda Biological reported a revenue of 707 million yuan for the first half of 2025, a year-on-year decrease of 19.75% [2] - The net profit attributable to the parent company was 122 million yuan, down 44.47% year-on-year [2] Shareholder Information - As of June 30, the number of shareholders decreased by 0.42% to 25,300, while the average circulating shares per person increased by 121.52% to 16,431 shares [2] - The company has distributed a total of 1.492 billion yuan in dividends since its A-share listing, with 1.075 billion yuan distributed over the past three years [2]